Monday, May 21, 2018
 
 
Company News: Page (1) of 1 - 03/16/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Progressive Care to Present at The Wall Street Investor Forum 26th Annual Investor Conference

(March 16, 2018)

MIAMI, March 16, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. (OTCQB:RXMD), a healthcare services and technology company, announced today that it will be presenting at The Wall Street Investor Forum 26th Annual Investor Conference in New York City at The University Club of NYC at 12:35 PM EDT on March 22, 2018. S. Parikh Mars, CEO will be presenting, as well as meeting with investors.

The conference presentation will be broadcast live a link to which will be available on our website http://www.progressivecareus.com.

What to Expect at The Wall Street Investor Forum 26th Annual Investor Conference:

The Wall Street Investor Forum hosts 40-minute presentation and Q/A sessions immediately followed by 40-minute breakout sessions.  There are also meetings taking place all day, but we do not schedule those. This conference will be held at the University Club of NYC on 5th Avenue and 54th Street. 

Get connected and stay in touch with us on social media:

Progressive Care Inc.

https://www.facebook.com/ProgressiveCareUS/https://twitter.com/ProgressCareUS

PharmCo, LLC


https://www.facebook.com/pharmcorx/
https://twitter.com/PharmCoRx

About Progressive Care

Progressive Care Inc. (OTCQB:RXMD), through its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, is a South Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long term care facilities, administration and practice management, utilization management, quality assurance, EHR Implementation, billing and coding, and health practice risk management.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

CONTACT: ContactArmen KarapetyanSenior Advisor Business [email protected]ww.pharmcopharmacy.com

Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
  • Regenerative Medicine Market Analysis Study Found Huge Boom By Rising Prevalence Of Chronic Diseases And Genetic Disorders Till 2025: Grand View Research,Inc.
  • Global Molecular Diagnostics Markets, 2016-2024 - Focus on Infectious Disease Testing, Blood Screening, Cancer Screening & Other Applications
  • Global Sleep Apnea Diagnostic and Therapeutic Devices Strategic Business Report 2018
  • Global Sleep Apnea Diagnostic and Therapeutic Devices: 2016/18-2024 Strategic Business Analysis & Forecast Report - mHealth-Enabled Sleep Tracking Devices Gain Ground

    Cancer
  • Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.
  • Altogen Labs xenograft services for drug development studies of anti-cancer therapeutics
  • HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage
  • Dr. Haydee Gonzalez Hidalgo joins The Oncology Institute of Hope and Innovation
  • eClinical Solutions Market Size Is Projected To Reach $13 Billion By 2024
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines